Rajan Rajabalaya and Li-Qun Tor and Sheba David
Formulation and in vitro Evaluation of Ondansetron Hydrochloride Matrix Transdermal Systems Using Ethyl CellulosePolyvinyl Pyrrolidone Polymer Blends
667 - 671
2012
6
12
International Journal of Pharmacological and Pharmaceutical Sciences
https://publications.waset.org/pdf/12020
https://publications.waset.org/vol/72
World Academy of Science, Engineering and Technology
Transdermal delivery of ondansetron hydrochloride (OdHCl) can prevent the problems encountered with oral ondansetron. In previously conducted studies, effect of amount of polyvinyl pyrrolidone, permeation enhancer and casting solvent on the physicochemical properties on OdHCl were investigated. It is feasible to develop ondansetron transdermal patch by using ethyl cellulose and polyvinyl pyrrolidone with dibutyl pthalate as plasticizer, however, the desired flux is not achieved. The primary aim of this study is to use dimethyl succinate (DMS) and propylene glycol that are not incorporated in previous studies to determine their effect on the physicochemical properties of an OdHCl transdermal patch using ethyl cellulose and polyvinyl pyrrolidone. This study also investigates the effect of permeation enhancer (eugenol and phosphatidylcholine) on the release of OdHCl. The results showed that propylene glycol is a more suitable plasticizer compared to DMS in the fabrication of OdHCl transdermal patch using ethyl cellulose and polyvinyl pyrrolidone as polymers. Propylene glycol containing patch has optimum drug content, thickness, moisture content and water absorption, tensile strength, and a better release profile than DMS. Eugenol and phosphatidylcholine can increase release of OdHCl from the patches. From the physicochemical result and permeation profile, a combination of 350mg of ethyl cellulose, 150mg polyvinyl pyrrolidone, 3 of total polymer weight of eugenol, and 40 of total polymer weight of propylene glycol is the most suitable formulation to develop an OdHCl patch. OdHCl release did not increase with increasing the percentage of plasticiser. DMS 4, PG 4, DMS 9, PG 9, DMS 14, and PG 14 gave better release profiles where using 300mg 0mg, 300mg 100mg, and 350mg 150mg of EC PVP. Thus, 40 of PG or DMS appeared to be the optimum amount of plasticiser when the above combination where EC PVP was used. It was concluded from the study that a patch formulation containing 350mg EC, 150mg PVP, 40 PG and 3 eugenol is the best transdermal matrix patch compositions for the uniform and continuous releasepermeation of OdHCl over an extended period. This patch design can be used for further pharmacokinetic and pharmacodynamic studies in suitable animal models.
Open Science Index 72, 2012